ID   KMS-11R
AC   CVCL_D705
DR   cancercelllines; CVCL_D705
DR   Cosmic; 1740214
DR   Wikidata; Q54900167
RX   PubMed=22869148;
CC   Population: Japanese.
CC   Characteristics: Produces IgG kappa.
CC   Selected for resistance to: AZ12908010 (AZ8010).
CC   Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5739; IGKV1-37; Name(s)=IGKV1-37-IGKJ4 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5816; IGKV3-15; Name(s)=IGKV3-15-IGKJ5 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr373Cys (c.1118A>G); ClinVar=VCV000016342; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*3; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2989 ! KMS-11
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 15
//
RX   PubMed=22869148; DOI=10.1038/onc.2012.319;
RA   Chell V., Balmanno K., Little A.S., Wilson M., Andrews S.,
RA   Blockley L., Hampson M., Gavine P.R., Cook S.J.;
RT   "Tumour cell responses to new fibroblast growth factor receptor
RT   tyrosine kinase inhibitors and identification of a gatekeeper mutation
RT   in FGFR3 as a mechanism of acquired resistance.";
RL   Oncogene 32:3059-3070(2013).
//